Rhabdomyolysis and coma associated with amisulpride: A probable atypical presentation of neuroleptic malignant syndrome

Journal of Clinical Psychiatry

Volumn 65, Issue 12, 2004, Pages 1724-1725

  Cem Atbasoglu, E ^a   Ozguven, Halise Devrimci ^a   Saka, Meram Can ^a   Goker, Ceren ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DRUG DERIVATIVE; NEUROLEPTIC AGENT; SULPIRIDE; SULTOPRIDE;

ADULT; BLOOD; CASE REPORT; CHEMICALLY INDUCED DISORDER; COMA; FEMALE; HUMAN; LETTER; LEUKOCYTOSIS; NEUROLEPTIC MALIGNANT SYNDROME; RHABDOMYOLYSIS; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; COMA; CREATINE KINASE; FEMALE; HUMANS; LEUKOCYTOSIS; NEUROLEPTIC MALIGNANT SYNDROME; RHABDOMYOLYSIS; SCHIZOPHRENIA; SULPIRIDE;

EID: 13744256630     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n1219f     Document Type: Letter

References (5)

1. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142:1137-1145
2. Bottlender R, Jager M, Hofschuster E, et al. Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient. Pharmacopsychiatry 2002;35:119-121
3. Farver DK. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf 2003;2:21-35
4. Rundell JR, Wise MG. Neuroleptic malignant syndrome. Important Pharmacological Issues in Consultation Psychiatry. Washington, DC: American Psychiatric Press; 2000:180-190
5. Nopoulos P, Flaum M, Miller D. Atypical neuroleptic malignant syndrome (NMS) with an atypical neuroleptic: clozapine-induced NMS without rigidity. Ann Clin Psychiatry 1990;2:251-253